Efficacy and safety of lemborexant as an alternative drug for patients with insomnia taking gamma‐aminobutyric acid–benzodiazepine receptor agonists or suvorexant

DOI Web Site PubMed 被引用文献1件
  • Kazumaro Okino
    Mental Care Center Showa University Northern Yokohama Hospital Yokohama‐shi Kanagawa‐ken Japan
  • Hirohisa Suzuki
    Department of Neuropsychiatry Showa University School of Medicine Shinagawa‐ku Tokyo‐to Japan
  • Hiroi Tomioka
    Mental Care Center Showa University Northern Yokohama Hospital Yokohama‐shi Kanagawa‐ken Japan
  • Kenji Sanada
    Department of Neuropsychiatry Showa University School of Medicine Shinagawa‐ku Tokyo‐to Japan
  • Keita Kawai
    Mental Care Center Showa University Northern Yokohama Hospital Yokohama‐shi Kanagawa‐ken Japan
  • Akira Iwanami
    Department of Neuropsychiatry Showa University School of Medicine Shinagawa‐ku Tokyo‐to Japan
  • Atsuko Inamoto
    Mental Care Center Showa University Northern Yokohama Hospital Yokohama‐shi Kanagawa‐ken Japan

この論文をさがす

説明

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Although gamma‐aminobutyric acid–benzodiazepine (GABA‐BZ) receptor agonists are used to treat insomnia, their long‐term or high‐dosage use causes adverse events. Nevertheless, evidence regarding the discontinuation and replacement of GABA‐BZ receptor agonists with alternative agents is lacking. Suvorexant (SUX), an existing orexin receptor antagonist, is effective in preventing nocturnal awakening in 70%–75% of patients with insomnia.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The novel dual orexin receptor antagonist lemborexant (LEM) has fewer adverse effects than GABA‐BZ receptor agonists. Therefore, in this retrospective study, we categorised patients taking GABA‐BZ receptor agonists and SUX into LEM‐treated (switched) and non‐treated (non‐switched) groups and compared their outcomes over a 12‐week period.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The GABA‐BZ group (<jats:italic>N</jats:italic> = 59) comprised 34 ‘switched’ and 25 ‘non‐switched’ and the SUX group (<jats:italic>N</jats:italic> = 14) comprised 6 ‘switched’ and 8 ‘non‐switched’ patients. A mixed model showed a significant diazepam equivalence reduction in patients taking GABA‐BZ receptor agonists and improved Athens Insomnia Scale score in those taking SUX. The safety and tolerability of GABA‐BZ receptor agonists and SUX were high, and no serious adverse effects were observed after switching to LEM.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Lemborexant may be a useful alternative for long‐term GABA‐BZ receptor agonist users. For SUX, the number of cases (<jats:italic>N</jats:italic> = 6) was insufficient to draw definite conclusions.</jats:p></jats:sec>

収録刊行物

被引用文献 (1)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ